Peptide vaccines incorporate one or more short or long amino acid sequences as tumor antigens, combined with a vaccine adjuvant. Thus, they fall broadly into the category of defined antigen vaccines, along with vaccines using protein, protein subunits, DNA, or RNA. They remain one of the most immunogenic approaches, based on measures of T-cell response in the blood or in draining lymph nodes. However, existing peptide vaccines have had limited success at inducing clinical tumor regressions, despite reliable induction of T-cell responses. Several new developments offer promise for improving peptide vaccines, including use of long peptides, optimization of adjuvants including toll-like receptor agonists, and combination with systemic therapies that may reduce tumor-associated immune dysfunction, such as blockade of PD-1/PD-L1 interactions. To apply these new approaches optimally, it will be critical to study their effects in the context of defined antigens, for which peptide vaccines are optimal.
P eptide vaccines for cancer offer the promise of inducing T cells reactive to well-characterized tumor antigens and also enabling assessment of the vaccination's effect by monitoring antigen-specific T-cell responses. Cancer cells express peptide antigens recognized by CD8+ cytotoxic T lymphocytes (CTLs), 1 which are typically 8 to 10 amino acids long and are presented in association with class I major histocompatibility complex (MHC) molecules. The peptides recognized by helper (CD4+) T cells are presented in association with class II MHC molecules and are usually longer (13Y18 amino acids in length), although peptide elution studies have indicated no apparent restriction on peptide length. For melanoma, the melanocytic differentiation proteins and the cancerYtestis antigens are the most common source proteins for these defined shared peptide antigens. Now, a large number of peptide epitopes recognized by melanomareactive human CTL and helper T cells are known, 2,3 making it possible to design vaccines using these antigens. We and others have found that selected peptides can induce circulating T-cell responses in most patients 4, 5 and that vaccination with a mixture of peptides is immunogenic in up to 100% of patients. 4 The magnitude of T-cell responses sometimes is substantial, with 1% to 5% of circulating CD8 T cells reactive to single antigens, 6Y9 which rivals the magnitude of T-cell responses to individual cytomegalovirus antigens in humans 10 ; however, responses in most patients are 1 to 2 orders of magnitude lower, which may or may not be adequate for clinical benefit. T-cell responses to vaccines may be durable for months or years but are at least as likely to be transient, sometimes declining even while still receiving vaccines. 11 However, T cells induced by vaccination can recognize and lyse melanoma cells expressing the relevant protein and MHC. 12, 13 Thus, peptide vaccines induce promising immunogenicity. However, the transience and low magnitude of responses in many patients presents a need for improving the immunogenicity and for ensuring that memory responses are induced.
Clinically, there have been durable clinical responses in some patients receiving melanoma vaccines, suggesting the potential for clinical activity. 14 However, overall clinical response rates are only approximately 3% to 5%. 15 Thus, vaccines are not optimized: the antigens and the adjuvants may both be improved. Also, circulating immune responses have not consistently correlated with clinical outcome. 4, 16 Arguably, that is not surprising, especially in the setting of advanced tumor burden. Both antigenic heterogeneity and tumor-associated immune dysfunction are characteristic of the tumor microenvironment. Adoptive therapy with T-cell clones specific for a single antigen has led to eradication of melanoma cells expressing that antigen, but the tumors have not regressed because of the persistence of antigen-loss variants. 17 Furthermore, T cells infiltrating tumor deposits are commonly found to be anergic or poorly responsive to antigenic stimulation, leading to the perception that the tumor microenvironment is hostile to the T-cell response. 18 Effective immune therapy may require induction of T-cell responses to multiple numbers of antigens simultaneously and maintenance of T-cell activation in the tumor deposits. Combination with approaches to block immunoregulatory mechanisms may well also be needed for immune therapy to be most successful.
ADVANTAGES OF PEPTIDE VACCINES
There are several advantages of peptide vaccines over other cancer vaccine approaches (Table 1) . Aside from the ease of synthesizing them, and their safety demonstrated in many trials, they have been effective at inducing T-cell responses. Short peptides (typically 9 amino acid residues) bind to class I MHC molecules and induce CD8 T cells that can lyse melanoma cells expressing the cognate MHC and peptide. 12, 13 Immune response rates vary, depending on the peptides and adjuvants used and depending on the assay method. However, immune response rates approaching 100% can be achieved, 4, 8, 19, 20 and the proportion of CD8+ cells responding to individual peptide antigens can exceed 1%. 7Y9,20 Although MHC restriction of individual peptides limits their use to a subset of patients, we have found that mixtures of a dozen peptides restricted by HLA-A1, -A2, -A3, or -A11 can be prepared as a stable mixture 21 and can induce immune responses in the 85% of patients with melanoma who express one or more of those MHC molecules, 4, 8, 20 without negative effects from competition among the peptides. 4 Other experience supports the ability to induce T-cell responses to multiple peptides when vaccinating with peptide mixtures. 22 
LIMITATIONS OF PEPTIDE VACCINES
Short peptides restricted by class I MHC molecules can bind directly into the peptide-binding groove on the exposed surface of the appropriate class I MHC molecule. In vivo, when a peptide vaccine is administered into the subcutaneous tissue (or other sites), the peptides may be able to bind to numerous types of cells, only a few of which are professional antigen-presenting cell (APC). When they bind to nonprofessional APC (eg, fibroblasts), they are presented without optimal costimulation; presentation of antigen in this way can even be toleragenic. Thus, there is concern that the effectiveness of vaccination with short peptides may be limited by this phenomenon. Also, these short peptides have little or no tertiary structure and are thus subject to rapid degradation by tissue and serum peptidases. We have estimated the half-life of a MelanA/MART-1 peptide in fresh human plasma to be approximately 22 seconds and found that both exopeptidases and endopeptidases were involved in the degradation. It is possible that the low magnitude and transience of T-cell responses observed in many patients vaccinated with short peptides may be explained in part by rapid degradation of these peptides in vivo, before they can be presented by professional APC, and also by suboptimal antigen presentation when it occurs.
Another factor is that when a vaccine is administered in the skin, it is generally believed that antigen presentation depends on dendritic cells (DCs) bearing the antigen to migrate to the regional draining nodes and to present the antigen there to naive circulating lymphocytes. When an antigen is presented by DCs that have taken up a whole protein or DNA, the peptide of interest is going to be presented on an ongoing basis because it is generated inside the cell over time and presented on MHC. However, when a short peptide is used, its ability to be presented to T cells in the draining node depends on its ability to remain bound to the MHC; so short peptides with low affinity for the MHC may be less immunogenic than they would be if they were more continuously being presented, for which one example may be gp100 280Y288 . 23, 24 
SINGLE VERSUS MULTIPLE PEPTIDES
Melanomas often lose expression of one or all melanocytic differentiation antigens as they progress, 25 and cancerYtestis antigens are expressed only in a subset of patients. Thus, no single antigen will be adequate for all melanomas. Also, antigenic heterogeneity and antigen loss phenotypes are common; so even if a melanoma expresses a specific antigen, some of the cells in that tumor may not express it. Thus, immunologic control of melanoma likely requires a broad immune response against multiple antigens. It is hypothesized that an effective immune response against a single antigen can induce epitope spreadingV induction of immune responses against other antigens. However, it is also possible for vaccines to target multiple antigens directly.
In developing multipeptide vaccines, there has been some concern that if multiple peptides binding the same MHC molecule are coadministered, binding of lower-affinity peptides to the MHC may be competitively inhibited by higher-affinity peptides. Because of this concern, multipeptide vaccines at some centers have been administered so that each peptide is administered at a different body site. 26 This approach will become increasingly unwieldy if the number of peptides exceeds 3 or 4. In preclinical studies from our group, we have found that competition among peptides for MHC binding does not significantly inhibit T-cell induction or T-cell effector function. 27, 28 On the other hand, a clinical study raised concern about the effect of mixing the peptides YMDGTMSQV (tyrosinase 369Y377 ) and IMDQVPFSV (gp100 209Y2M 29 ) . That report was based on 2 sequential clinical trials, so that there may have been other variables at play. In a prospective randomized trial, we tested the immunogenicity of a 12-peptide vaccine compared with a vaccine containing just 4 of those 12 peptides. We found that immunogenicity of the index peptides was maintained in those patients receiving the 12-peptide vaccine, and there was also a marked and significant increase in cumulative T-cell reactivity toward the 12-peptide vaccine. Thus, addition of 2 to 3 peptides binding the same class I MHC allele does not inhibit immunogenicity of an index peptide when administered at equimolar concentrations, and use of multiple peptides in a cancer vaccine is supported.
ADDITION OF CD4 EPITOPES

Role of CD4+ Helper T Lymphocytes in Anti-Tumor Immune Responses
Most peptide vaccines have been designed to activate the CD8+ cytotoxic T-cell arm of the host immune system, which 
Slingluff
The Cancer Journal & Volume 17, Number 5, September/October 2011 plays a critical role in tumor eradication. 30Y34 However, some recent approaches target CD4+ T H cells. This is based in part on results from earlier studies that demonstrated depletion of CD4+ T cells abrogates all or part of protective immune response to vaccines. 35 Furthermore, adoptive therapy with CD4+ T cells has been shown to induce tumor protection in some model systems, 36 and there has been anecdotal clinical benefit in a patient after adoptive therapy with melanoma-reactive CD4+ T cells. 37 Thus, protective immunity induced by tumor cell vaccines and by adoptive T-cell therapy may be mediated by CD4+ T cells.
Natural immune responses to pathogens consist of an integrated response including T H responses to epitopes presented by class II MHC molecules and CTL responses to epitopes presented by class I MHC molecules. 38 T H cells can activate DCs for heightened antigen presentation, causing the DC to secrete interleukin 12 (IL-2) and other cytokines that may help to direct the immune response. Furthermore, strong T H 1 help produces the proper cytokine milieu (interferon F [IFN-F], tumor necrosis factor >, IL-2), which is critical to the induction of immunemediated tumor destruction. 39, 40 In addition, T H responses are believed to be involved in the establishment of memory responses. 41 Thus, there is rationale for induction of CD4+ T cells with cancer vaccines, either on their own or in combination with stimulation of CD8+ T cells.
Induction of Nonspecific T-Cell Help
One approach to induction of CD4+ T-cell help is to use molecules that stimulate CD4+ T-cell responses that are not specific for cancer antigens but may stimulate recall responses or other nonspecific help. Commonly used approaches have been to add keyhole limpet hemocyanin (KLH), 42Y44 PADRE peptide, 45 or a tetanus toxoid helper peptide. 46, 47 In 1 study, CD8+ T-cell responses to class I MHCYassociated tyrosinase peptides seemed to be increased by coadministration of KLH. 44 Although KLH may have broader adjuvant properties than simply the effects on helper T cells, these data suggest a benefit of nonspecific helper peptide stimulation. We have used a peptide epitope for T-helper cells derived from tetanus toxoid (tetanus helper peptide) modified from the reported sequence by adding an alanine residue to the N-terminus to avoid spontaneous conversion of glutamine at the N-terminus to pyroglutamate and to increase stability (AQYIKANSKFIGITEL). Responses to that peptide are induced in more than 90% of patients when vaccinating with incomplete Freund's adjuvant (IFA), 8, 20 and these responses seem to be predominantly T H 1 responses. 48 
Induction of Melanoma-Specific T-Cell Help
HLA-DRYrestricted peptides have been identified from melanoma-associated proteins, 49Y55 but there is limited in vivo human experience with them. Epitopes for CD4+ helper T cells are typically longer than those for CD8+ T cells, and they are promiscuous in binding to many different class II MHC molecules. Most prior studies with these ''helper'' peptides used only 1 or 2 peptides, and they limited enrollment to a single MHC class II allele. 56Y58 We have tested a multipeptide helper peptide vaccine to stimulate melanoma-reactive CD4+ T cells, using 6 melanoma helper peptides (6MHP) from melanocytic differentiation antigens and cancer testis antigens, restricted by HLA-DR molecules (Fig. 1 ). 14 The findings demonstrate safety and immunogenicity. Immune responses to the 6MHP pool were detected in more than 80% of patients, across a wide range of HLA-DR molecules, suggesting that these peptides may be broadly relevant to the immune response to melanoma. 14 Findings also suggest promiscuity of these helper peptides across a wider range of HLA-DR molecules than originally reported. Some immune responses were detectable through week 39, more than 6 months after the last vaccine, suggesting induction of memory in those patients. However, the immune responses were transient in some other cases, suggesting immune regulatory processes that should be identified and targeted for combination immunotherapy in the future.
In addition to in vitro evidence of immunogenicity of this 6-helper peptide vaccine, we also observed in vivo evidence of immune reactivity, based on delayed type hypersensitivity responses in 7 (29%) of 24 evaluable patients. There were also autoimmune reactivities in 21% of patients, including vitiligo in 10%, without associated symptoms. Durable objective clinical responses were observed in 2 of 17 patients with measurable disease, and durable disease stabilization occurred in 2 additional patients. 14 Immune responses were identified to 6MHP for all patients with delayed type hypersensitivity responses, all patients with autoimmune toxicities, and all 4 patients with partial clinical responses or stable disease. Together, these data suggest both biologic activity and evidence of clinical activity. This phase I/II trial provided data supporting larger studies of this 6 helper peptide mixture with or without immunogens to stimulate CD8+ T cells.
Combining Class I MHCYRestricted Peptides and Class II MHCYRestricted Peptides in Vaccines
Because CD4+ cells have a fundamental and comprehensive role in initiation and maintenance of cytotoxic T-cell responses, 41 vaccination with cytotoxic T-cell epitopes may be more successful when the vaccine includes helper epitopes from the same protein(s) rather than with nonspecific helper epitopes. In patients with human immunodeficiency virus (HIV) infection, there are data suggesting that induction of CD4+ responses to HIVantigens with an HIV-specific peptide augments HIV-specific CD8+ T-cell reactivity. 59 Considering the strong rationale for the induction of helper T-cell responses to melanoma antigens, and human data supporting the approach in the HIV setting, it is rational to test whether vaccination with melanoma-associated helper peptides that can induce antigen-reactive CD4+ T-cell responses can increase CD8+ responses compared to vaccination with a nonspecific helper peptide. Several trials have tested this concept in the setting of a single class IYrestricted peptide and a single class IIYrestricted peptide. In a study with the gp100 44Y59 helper peptide, helper T-cell responses were not induced, but CTL responses were paradoxically reduced compared to a prior study. 60 That report raises a question of whether the addition of helper peptides may be harmful, rather than helpful, to the anti-tumor response. However, the conclusions of that report were confounded by several critical weaknesses: (1) comparison of outcomes between 2 nonrandomized pilot studies only, (2) marked differences in the proportion of patients with prior chemotherapy between the study groups (23% vs 58%), (3) very low immunogenicity of the MART-1 peptide in both arms, raising questions about vaccine immunogenicity, (4) complete absence of immunogenicity of the DR-restricted gp100 peptide, and (5) use of high-dose IL-2 in some patients, which may alter measured responses. 11 In another study with class II peptides only, that same gp100 peptide was not immunogenic, but another helper peptide, from MART-1/MelanA, was immunogenic. 61 That study did not assess the impact of the helper peptide responses on CTL responses to class I peptides, but there were some cytotoxic CD4+ responses generated. 61 In another study, in epithelial cancers, with Her-2/neu peptides comprising overlapping epitopes for CD4+ and CD8+ T-cells, CD8+ T-cell responses were observed, but CD4+ responses were not reported. 62 To address formally the question of whether addition of melanoma helper peptides would increase CD8 T-cell responses in a multipeptide vaccine, we have performed a multicenter randomized trial, Mel44, which enrolled 167 eligible patients with resected stage IIB to IV melanoma, who were randomized to 4 vaccination groups. Patients were vaccinated with 12 MHC class IYrestricted melanoma peptides (12MP) to stimulate CD8+ T cells and randomized to receive a tetanus helper peptide or a mixture of 6MHP to stimulate CD4+ T cells. Before vaccination, patients were also randomly assigned to receive cyclophosphamide (CY) pretreatment or not. T-cell responses were assessed by ex vivo IFN-F enzyme-linked immunosorbent spot assay. Vaccination with 12MP plus tetanus induced CD8+ T-cell responses in 78% of patients and CD4+ T-cell responses to tetanus peptide in 93%. Vaccination with 12MP plus 6MHP induced CD8+ responses in 19% and CD4+ responses to 6MHP in 48%. CY had no significant effect on T-cell responses. Thus, in this adjuvant setting, melanoma-associated helper peptides paradoxically decreased CD8+ T-cell responses to a melanoma vaccine (P G 0.001), and CY pretreatment had no detectable immunologic or clinical effect. 20 Similar negative effects of combining helper peptides with class I peptides have been observed in an Eastern Cooperative Oncology trial 1602. 63 Possible explanations for negative effects on CD8 responses include modulation of homing receptor (HR) expression or induction of antigen-specific regulatory T cells, and new data also raise the possibility that these negative results may be explained in part by effects of the vaccine adjuvants, locally at the site of vaccination.
PHOSPHO-PEPTIDES
As immune therapy becomes an effective and accepted approach for durable clinical regressions of melanoma and other cancers, the other most exciting area of new drug development for cancer therapy is in targeted therapies that inhibit molecular activation that is critical to the transformed phenotype. Most of the targeted therapies, including those of the MEK/BRAF pathway, are focused on blocking the activity of bioactive phosphoproteins. As effective as these therapies can be, rapid disease progression can occur after initial responses. A promising approach would be to combine such targeted therapies with immune therapy that is active against the phosphoproteins that maintain the malignant transformed phenotype. A new class of peptides being brought to the clinic in the near future are peptides that contain phosphoserine or phosphotyrosine residues and which thus represent biologically active phosphoproteins that may be critical to the transformed phenotype. 64Y66 They offer promise for a new and important class of antigen to target in future cancer vaccines.
ADJUVANTS FOR PEPTIDE VACCINES
IFA as Immunologic Adjuvant
This article is focused on peptide vaccines, but the peptides cannot be isolated from their adjuvants. Surprisingly, effects of immunologic adjuvants in vivo in humans are not well understood. The most common adjuvant for peptide vaccines for melanoma has been IFA, commonly Montanide ISA-51 (Seppic, Inc, Paris, France). There have been questions about whether this is a reliable immunologic adjuvant. 67, 68 We have found it useful even in its newer formulation. 67 However, it is increasingly evident that effective immunotherapy depends on the quality of the adjuvant, whose optimization will require an understanding of its function in vivo in humans at the vaccine site microenvironment (VSME). In a study of vaccination with peptides in IFA, we found that 1 week after 1 vaccine, T H 2 cells (GATA-3+), but not T H 1 cells (T-bet+), were increased in number, suggesting that peptide vaccination in IFA may induce a T H 2-dominant VSME; this was supported also by induction of a large number of eosinophils at the vaccine site. Only after 3 vaccines was there conversion to a more balanced T H 1/T H 2 microenvironment. 69 Also, the frequency of FoxP3+ cells (putative regulatory T cells) increased with repeated vaccination. 69 The impact of FoxP3+ cells here can be debated, but this adjuvant does not seem to induce an optimal immunologic milieu at the VSME. These findings may contribute to the low magnitude and transience of CD8+ T-cell responses to short peptide vaccines administered in IFA. An intriguing hypothesis also is that the chronic inflammation induced by IFA can serve to attract antigen-specific T cells back to the vaccine site, thereby depleting them from circulation and reducing the number that may traffic to sites of metastasis. 70 These findings together support seeking new adjuvants.
Toll-Like Receptor Agonists as Vaccine Adjuvants
The critical functions of vaccine adjuvants are not known but may include activation of innate immunity, optimization of antigen presentation, recruitment of DCs, and creating a cytokine environment that supports the desired immunologic outcome. Toll-like receptors (TLRs) are early mediators of innate immune responses to pathogens. They may improve vaccination efficacy, through activation of innate immune mechanisms, mediated in part by IFN-> signaling and by activating DCs. Tolllike receptor agonists offer the potential to improve the magnitude and persistence of anti-tumor T-cell responses 9 ; however, most trials of TLR agonists have been limited to use of 1 TLR agonist and have not defined molecular and cellular effects at the VSME. Several TLR agonists may be effective vaccine adjuvants, including agonists for TLR 3, 4, 7, 8, and 9. In murine models, the combination of TLR agonists and IFA has strong immunologic adjuvant properties with peptide vaccines. Murine and human studies have also suggested value of combining agonists for 2 to 3 TLRs. 71, 72 Future human studies need to evaluate whether individual agonists for TLR 3, 4, 7, 8, or 9 are better adjuvants than IFA alone and also whether these TLR agonists alone or together may be more immunogenic with or without IFA. Toll-like receptor agonists are likely to support a
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The Cancer Journal & Volume 17, Number 5, September/October 2011 strong T H 1 environment. 73Y75 Some data suggest that TLR8 agonists may decrease regulatory T cells, 76 although these data have not been replicated. Vaccination of humans with the oligonucleotide CpG7909 (TLR9 agonist) increases CD8 T-cell responses to a short peptide when combined with IFA, 9 and vaccination with peptides and the TLR3 agonist polyICLC also shows promise in murine and human studies. 77 Current trials with a MAGE-A3 protein use a complex adjuvant system that includes the TLR4 agonist monophosphoryl lipid A and the TLR9 agonist CpG oligonucleotide, in addition to the saponin QS-21. 78 It is not yet known if this approach is optimal or if it will be feasible or effective also for peptide vaccines. However, it does seem likely that some use of TLR agonists will be helpful to increase the immunogenicity of peptide vaccines.
Ligation of CD40
Toll-like receptor activation synergizes with ligation of CD40 on DC; combining TLR agonists and CD40 ligation may augment immune responses to vaccines. 79 In humans, antibody to CD40 may induce CD40 ligation, but many cells express CD40 and thus serve as sinks for systemic CD40 antibody. Another possible approach to ligate CD40 specifically on DC in the VSME and in vaccine-draining lymph nodes (VDLNs) is to take a lesson from physiologic immune responses to pathogens. When pathogens are encountered naturally in the skin, CD4 T cells are activated and upregulate CD40L, which then binds and activates CD40 to license DC. Thus, activation of CD4+ cells in the VSME and VDLN will upregulate CD40L on those cells. CD40L+ CD4 cells in turn license professional APC (DC) in tissues where antigen is presented. Progress in cancer vaccine development thus likely requires optimizing approaches to induce CD4+ T cells in the VSME and VDLN. The encouraging results of vaccinating with melanoma helper peptides alone are in contrast to the disappointing findings after vaccinating with melanoma helper peptides mixed with peptides to stimulate CD8+ T cells. Alteration in adjuvants may be critical to improving the ability to combine approaches to stimulate CD4+ T cells and CD8+ T cells.
LONG VERSUS SHORT PEPTIDES
Short peptides may bind directly to MHC molecules on cells that are not professional APCs, thereby potentially inducing tolerance or anergy. 80, 81 In contrast, recent work with long (30-mer) peptides that encompass short minimal epitopes suggests that these longer peptides may be more effective immunogens than the minimal peptides. The extra length contributes to a tertiary structure that may protect from exopeptidasemediated degradation, and they are too long to be presented directly on MHC; so they must be internalized by professional APC and processed for presentation (eg, CD11c+ DC). 82Y85 Unlike short peptides, long peptides induce memory CD8+ T-cell responses that are boosted dramatically on repeat vaccination in mice and induce substantially improved tumor control compared to vaccination with short peptides. 83, 86 Induction of helper T cells reactive to epitopes within the long peptide has been implicated as necessary for long-term T-cell memory. 86 This is supported by the finding that the improved immunologic responses and tumor control are blocked in mice knocked out for CD4 or for CD40. A vaccine using long (30-mer) peptides from human papillomavirus type 16 for squamous vulvar neoplasia has induced clinical regressions in most patients, supporting clinical activity of long peptide vaccines. 87 Using these long peptides promises to induce a broad and more durable adaptive immune responses against multiple antigens.
COMBINATION IMMUNE THERAPY
Even from the most optimistic perspective, it is unlikely that vaccines alone will provide durable clinical benefit for most melanoma patients; however, it is likely that combination with other effective agents may lead to cumulative or synergistic benefit in large proportions of patients. New immunomodulatory agents with clinical activity are now available for use in melanoma. Among these, perhaps the most exciting are antibodies that block PD-1/PD-L1 interactions. The National Cancer Institute's Immunotherapy Agent Workshop prioritized therapeutic agents for use in cancer immunotherapy. AntiYPD-1 agents were ranked no. 2. 88 There are at least 3 antibodies to PD-1 in clinical trials (MDX-1106, CT-011, and MK-3475). Clinical experience with one of these is that it induces objective clinical responses in 30% of patients with advanced melanoma, with high durability, and a safety profile that may be better than that of CTLA-4 antibody, and with MTD not reached in initial studies. 89, 90 PD-1 is expressed by activated T cells, B cells, and some myeloid cells. Its ligand, PD-L1, is expressed on many peripheral tissues and cell types, including melanoma cells. Its unique effects (compared to CTLA-4, for example) may be mediated in part by its expression in peripheral tissues, including the tumor. 91 PD-L1's expression in peripheral tissues seems critical to maintaining peripheral tolerance. 91 PD-1/PD-L1 interaction can limit T-cell reactivity even long after initial activation, and its blockade can restore immune function. 91, 92 PD-1 ligation inhibits signaling through T-cell receptor activation; it depends on stimulation of the T-cell receptor at the time of PD-1/PD-L1/L2 ligation. 93 Thus, inhibition of PD-1/PD-L1 can be expected to improve dysfunction of tumor-reactive T cells in situ in the presence of tumor antigen and it may improve reactivity to vaccines given simultaneously or to chronic viral antigen (eg, cytomegalovirus) but may not affect memory responses to viral antigens in the absence of viral antigen (eg, influenza). PD-L1 expression also is induced by antigen-mediated immune reactivity. PD-1 also can alter T-cell movement, 94 and blockade of PD-1 can increase T-cell infiltration of peripheral tissues (eg, in autoimmunity models) 95, 96 and thus may be expected to affect T-cell HR expression or expression of HR ligands and may be expected to augment T-cell infiltration of melanoma metastases. Thus, PD-1/PD-L1 blockade has promise to increase T-cell activation in the VSME and in the tumor microenvironment while also enabling activated T cells to infiltrate metastases and to remain activated. Thus, there is strong rationale to combine an optimized peptide vaccine with an inhibitor of PD-1/PD-L1 interactions.
SUMMARY
Prospects for improving peptide vaccines include use of long peptides, modification of adjuvants, inclusion of new antigens, and combination therapy with other immunologically active agents. Evidence suggests that long peptides may be more immunogenic than short peptides, and studies evaluating them are underway. Current data suggest that long peptides may overcome many of the challenges with short peptide vaccines by inducing both CD4+ and CD8+ responses with more optimal antigen presentation and by enabling continued presentation of immunogenic but low-affinity peptides as antigen-loaded DC migrate to regional nodes. Toll-like receptor agonists may be more effective adjuvants than IFA, local or systemic granulocyte macrophage colony stimulating factor, or systemic IFN-F. Preclinical studies support the value of TLR agonists as vaccine adjuvants, and some clinical studies support the value of TLR3, TLR4, and TLR9 agonists, in particular. However, the optimal TLR agonist(s), dose, timing, and mode of delivery remain to be determined. Very little is known about the molecular and cellular effects of various adjuvants, at the vaccine site and in the vaccine-draining node; an important area of future studies is to understand the local effects of TLR agonists and how they mediate adjuvanticity. A large number of antigens are known, but few have been studied in vaccines. A new class of peptides being brought to the clinic in the near future are peptides that contain phosphoserine or phosphotyrosine residues, which represent biologically active phosphoproteins that may be critical to the transformed phenotype.
A major limitation of all immune therapy is the fact that the tumor microenvironment is hostile to T-cell infiltration, function, and survival. Thus, in addition to optimizing the immune response induced by peptide vaccines, there is a need to understand critical molecular mediators of T-cell trafficking to the tumor microenvironment and mediators of immune dysfunction in the tumor microenvironment. As evidence begins to accumulate for the therapeutic value of defined antigen vaccines, 87,97Y99 it seems likely that improvements in vaccine immunogenicity, in T-cell persistence, and in reversal of tumor-associated immune dysfunction will lead to improved therapeutic value of peptide vaccines in combination with optimal adjuvants and systemic immune modulation. Combinations of vaccines with IFN->, granulocyte macrophage colony stimulating factor, and CTLA-4 antibodies have not improved immune responses or clinical outcome compared with vaccine alone. 8, 16, 100, 101 On the other hand, combination of a peptide vaccine with high-dose IL-2 improved clinical response rate and progression-free survival and induced a strong trend to improved survival (P = 0.06). 99 Other clinically active agents offer promise to improve T-cell responses and clinical outcome. Candidates include antibodies to PD-1 or PD-L1, agonistic antibody to CD137, and cytokines that may support T-cell expansion and persistence, such as IL-7 and IL-15. As all of these new immune modulators are explored to augment cancer immunotherapy, studies on peptide vaccines will be particularly helpful because they are ideal for correlative studies of immune response to enable an understanding of the effects of each intervention.
